Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions — Oct 15th, 2024

argenx SE Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response VYVGART demonstrates consistent, favorable safety profile from follow-u...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... — Oct 9th, 2024

Total Operating Income: $489 million in Q2 2024. Product Net Sales: $478 million, attributed solely to MG patients. Regional Revenue Breakdown: $407 million in the US, $20 million in Japan, $35 million in EMEA, $14 million from China. Operating Expenses: $535 million in Q2, an increase of ...

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses' — Oct 15th, 2024

Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...

Discover October 2024's Stocks Estimated To Be Trading Below Fair Value — Oct 18th, 2024

As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, ide...

Zacks.com featured highlights include Argenx SE Alphatec and Olin — Oct 7th, 2024

For Immediate Release Chicago, IL – October 7, 2024 – Stocks in this week’s article are Argenx SE ARGX, Alphatec Holdings, Inc. ATEC and Olin Corp. OLN. 3 Best Earnings Acceleration Stocks to Buy for a Strong Q4 After grappling with recession fears, the Federal Reserve’s jumbo i...